Clinic at the University of Colorado, one of the nation's leading pulmonary medicine centers. He has worked at Roche, Merck and Amgen, where he gained successful experience in all phases of the R&D value chain. His early-stage R&D experience includes membership

only a recommendation, but there's little chance of the FDA going against the outside experts when the vote is this lopsided. For Amgen to get Xgeva's label expanded to an earlier indication, it will probably have to show that the earlier use extends survival.

they're talking about. Today, we're going to take a look at three headline-making ratings moves on Wall Street: Downgrades for Amgen (Nasdaq: AMGN ) and Cisco (Nasdaq: CSCO ) , balanced by a curious upgrade for Apollo Investment (Nasdaq: AINV ) . Let's dive

have a “neutral” rating on the company’s shares. Separately, analysts at Oppenheimer (NYSE: OPY) downgraded shares of Amgen from an “outperform” rating to a “perform” rating in a research note to investors on Thursday. Analysts at Zacks Investment Research

Sterne Agee is upping its earnings estimate and stock-price target for the oil and gas exploration company. The media giant exceeded earnings estimates for a 12th consecutive quarter, announced a stock buyback and raised its dividend. Jacob's Pillow, the c

News | News By Subject | News by Disease | News By Date | Search News Get Our Industry eNewsletter FREE email: 2/9/2012 8:10:58 AM Amgen Inc., the world’s biggest biotechnology company, failed to win the backing of a U.S. advisory panel for its drug to delay

Thursday, February 9, 11:07 AM Amgen (AMGN -1.2%) continues its slide on the back of the FDA's rejection of Xgeva yesterday, spurred on today by a downgrade to Perform at Oppenheimer, citing a lack of near-term catalysts for the drug maker over the near te

(Nasdaq: AMGN ) carries $14 billion of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road. Could this be the case with Amgen? Before we answer that, let's look at what

(AMGN) downgraded at Oppenheimer to Perform from Outperform, Oppenheimer said. Few upside drivers remaining in 2012. Arris (ARRS) upgraded at Collins Stewart from Neutral to Buy, Collins Stewart said. $15 price target. Moxi should still achieve full-year sales

quarter earnings per share of $1.19, 5 cents below the Zacks Consensus Estimate, but 3.5% above the year-ago period. However, Amgen provided better-than-expected guidance for 2012. The company expects earnings in the range of $5.90 - $6.15 per share on revenues